Benitec Biopharma Inc.

BNTC

Held by 1 specialist biotech fund

High short interest · No specialist buying

1 fund opened new positions. Next phase2 readout: Nov 2030. Short interest: 11.9% of float.

BiotechnologyCEO: Jerel A. BanksIPO: 2014Website ↗

Benitec Biopharma Inc., a development-stage biotechnology company, focuses on the development of novel genetic medicines. The company develops DNA-directed RNA interference based therapeutics for chronic and life-threatening human conditions. It is developing BB-301, an adeno-associated virus based gene therapy agent for treating oculopharyngeal muscular dystrophy; and BB-103 for the treatment of chronic hepatitis B virus infection. The company was incorporated in 1995 and is headquartered in Hayward, California.

Benitec Biopharma Inc.

Signal Score

Conviction + Catalyst

Fund Holdings

Short Interest

Catalysts

Activist Filings

Position Details

Know which insider moves are real

Insider Signals

Also Held by These Funds

Research Links

Related Research